Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
Articles

Papers, explained in our own words

Every entry summarises what the study set out to test, what it found and why it changes how we design delivery systems. Browse research and reviews or search the collection.

571 articles

Showing 1–1 of 1 articles · Keyword: Postmenopausal osteoporosis Clear keyword

Bioactive materials2026ResearchNon-viral Gene DeliveryDrug Delivery

1. Osteoporosis treatment via programmed delivery of IRF5 siRNA to macrophages in bone tissue combined with ROS scavenging

Chen Z, Wu J, Zhu Y, Tan A, Deng J, Niu Y, Et Al.

Postmenopausal osteoporosis (PO) is not merely a consequence of increased osteoclast activity. Estrogen deficiency induces oxidative stress and pro-inflammatory M1 macrophage polarization in bone tissue, thereby sustaining osteoclastogenic stimuli and pathological bone resorption. Interferon regulatory factor 5…

Read the article
Articles | Brilliant Blue Biosciences